A small-molecule inhibitor of the Wnt pathway (SM04690) as a potential disease modifying agent for the treatment of osteoarthritis of the knee - Deshmukh, V.; Hu, H.; Barroga, C.; Bossard, C.; KC, S.; Dellamary, L.; Stewart, J.; Chiu, K.; Ibanez, M.; Pedraza, M.; Seo, T.; Do, L.; et al. (Osteoarthritis and cartilage, 2018)
Keywords: ACLT; Animals; Anti-Inflammatory Agents - pharmacokinetics; Anti-Inflammatory Agents - pharmacology; Cartilage, Articular - physiology; Cell Differentiation - drug effects; Cells, Cultured; Chondrocyte; Chondrocytes - cytology; Chondrocytes - drug effects; Dimethyl Sulfoxide - pharmacology; DMOAD; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Indazoles - pharmacokinetics; Indazoles - pharmacology; Male; Osteoarthritis; Osteoarthritis, Knee - drug therapy; Pyridines - pharmacokinetics; Pyridines - pharmacology; Rats, Sprague-Dawley; Regeneration - drug effects; Rheumatology; Small molecule; Solvents - pharmacology; Wnt signaling; Wnt Signaling Pathway - drug effects; Wnt signaling; DMOAD; Small molecule; Chondrocyte; ACLT; Osteoarthritis